Home > Research > Subjects > Pharmacy & biomedical sciences > New medicines

Strathclyde Institute of Pharmacy & Biomedical Sciences

New medicines
The new medicines group uses a multidisciplinary approach to improve our understanding of
fundamental bioscience and identify novel therapeutic targets with the aim of developing novel research
tools and therapeutic interventions.

New targets for new treatments

Fundamentals group
This group is led byDr Trevor Bushell.

Our group works to increase our understanding of fundamental bioscience. The group aims to use the
knowledge to determine how it contributes to normal health and wellbeing and/or is altered under
pathophysiological conditions.

Determining how the body functions under both physiological and pathophysiological conditions will
further enhance our understanding of disease conditions. This helps us to identify potential novel
therapeutic targets that can be probed using available in vitro and in vivotechniques.

Our research incorporates a broad range of activity including cardiovascular, immunology, microbiology
and neuroscience. These all focus on the following activities in order to meet the aims of the Strathclyde
Institute of Pharmacy & Biomedical Sciences, the Faculty of Science and the University as a whole:

1. advance our fundamental understanding of complex biological processes

2. determine practical solutions to major challenges including healthier ageing and the control of
infectious diseases

3. use fundamental bioscience for better health across the life course, reducing the need for medical
and social intervention

4. utilise fundamental discovery science in order to develop innovative preventative and therapeutic
interventions in humans

5. develop solutions that underpin the healthcare and life sciences sectors

6. discover and apply new technologies and approaches to replace, reduce and refine the use of
animals for scientific purposes

7. identify and apply research into environmental areas of major economic and societal importance

8. apply the latest developments in our science and technology to health-related challenges

We perform research aimed at improving our knowledge of the fundamental mechanisms by which
organisms function, from microbes to man, and how this can be applied to identifying potential novel
therapeutic targets.

Our experts
Academics
Trevor Bushell
Jim Alexander
Susan Chalmers
Paul Coats
John Connolly
Graham Coombs
Margaret Cunningham
Robert Drummond
Katherine Duncan
Paul Herron
Paul Hoskisson
 Arnaud Javelle
Charles Kennedy
Catherine Lawrence
Owain Millington
Craig Roberts
Shuzo Sakata
Nick Tucker
Phil Winn
Christian Wozny
Jun Yu

Research staff
Morag Farqhar
Leena Nieminen
Katy McIntosh
Kirsty Ross
Gabriel Uguru
Gareth Westrop
Stuart Woods

Target validation & drug discovery

The objective of this group is to use medicinal chemistry, chemical biology and regenerative therapeutic
approaches to improve treatment of significant health needs, or that focus on developing research tools
that increase interrogative power of disease mechanisms and the efficiency of developing therapeutic
interventions.

We're focusing on rare inflammatory diseases that can be investigated from the standpoint of multiple
target pathways (for which we have expertise and assay platforms) that can be or are validated in
humans. We're building chemistry and clinical capacity to tackle these orphan status diseases with the
objective that we will be able to translate our optimised compounds into new medicines.

Our experts
Academics
Nigel Pyne
Hilary Carswell
Luke Chamberlain
 Ed Chan
Margaret Cunningham
Susan Currie
Sandy Gray
Billy Harnett
Miles Houslay
Hui-Rong Jiang
Simon Mackay
John McCarron
Andy Paul
Robin Plevin
Ben Pickard
Judy Pratt
Sue Pyne
Dino Rotondo
Eddie Rowan
Veronique Seidel
Martin Wiese

Research staff
Nahoum Anthony
Mark Barbour
Kara Bell
Giacomo Berretta
Stephanie Boomkamp
David Breen
Ros Brett
Carol Clements
James Doonan
Jennifer Greaves
Chris Lawson
Kimon Lemonidis
Anthony McCluskey
Neil McRitchie
Faisa Omar
Manuel Sanchez Santos
Mairi Sandison
Annette Sorensen
Christine Salaun
Rothwelle Tate
 Louise Young

Research areas

Better medicines
Better use of medicines

Contact us

Research Director
Marie Boyd
marie.boyd@strath.ac.uk

Fundamentals lead
Trevor Bushell
trevor.bushell@strath.ac.uk

Target validation & drug discovery lead

Nigel Pyne
n.j.pyne@strath.ac.uk

Home > Research > Subjects > Pharmacy & biomedical sciences > New medicines

Our faculties & departments

Engineering
Architecture
Biomedical Engineering
Chemical & Process Engineering
Civil & Environmental Engineering
Design, Manufacture & Engineering Management
Electronic & Electrical Engineering
Mechanical & Aerospace Engineering
Naval Architecture, Ocean & Marine Engineering

Humanities & Social Sciences

Centre for Lifelong Learning
Education
Government & Public Policy
Humanities
Law
Psychological Sciences & Health
Social Work & Social Policy

Science
Computer & Information Sciences
Mathematics & Statistics
Physics
Pure & Applied Chemistry
Strathclyde Institute of Pharmacy & Biomedical Sciences

Strathclyde Business School

Accounting & Finance
Corporate Connections
Economics
Human Resource Management
Hunter Centre for Entrepreneurship
Management Science
Marketing
MBA & International Division
Strategy & Organisation

Professional Services
Conferencing & Events
Estates Services
Finance Directorate
Human Resources
Information Services Directorate
Internal Audit
Research & Knowledge Exchange Services
Strategy & Policy
Student Experience & Enhancement Services
Occupational Health, Safety & Wellbeing

Online services
Staff email (Nemo)
Student email (@uni.strath.ac.uk)
Myplace
PEGASUS
PURE
Timetables
Lab availability
Telephone Directory
Report IT problems & systems Service page
The Hub
Service Catalogue
ULab

Quick links
Website Privacy Policy
Accessibility
 Equality
Vacancies
Freedom of information
Library
SharePoint
Strathcloud ShareFile
Students' Association
Careers

Mobile app
Download the app
Stay in touch

Contact us

The University of Strathclyde is a charitable body, registered in Scotland, number SC015263.